

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  B01D 61/00		A1	(11) International Publication Number: <b>WO 93/08904</b>
			(43) International Publication Date: 13 May 1993 (13.05.93)
<p>(21) International Application Number: <b>PCT/US92/09542</b></p> <p>(22) International Filing Date: 3 November 1992 (03.11.92)</p> <p>(30) Priority data: 787,067 4 November 1991 (04.11.91) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 787,067 (CIP) Filed on 4 November 1991 (04.11.91)</p> <p>(71) Applicant (for all designated States except US): PALL CORPORATION [US/US]; 2200 Northern Blvd., East Hills, NY 11548 (US).</p>		<p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only) : BORMANN, Thomas, J. [US/US]; 29 Cawfield Lane, Melville, NY 11747 (US). MATKOVICH, Vlado, Ivan [US/US]; 11 Old Estate Road, Glen Cove, NY 11542 (US). GSELL, Thomas, C. [US/US]; 40 Valentine Avenue, Glen Cove, NY 11542 (US). PALL, David, B. [US/US]; 5 Hickory Hill, Roslyn Estates, NY 11576 (US).</p> <p>(74) Agent: JAY, Jeremy, M.; Suite 300, 700 Thirteenth Street, N.W., Washington, DC 20005 (US).</p> <p>(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).</p>	
<p>Published <i>With international search report.</i></p>			
<p>(54) Title: DEVICE AND METHOD FOR SEPARATING PLASMA FROM A BIOLOGICAL FLUID</p> <p>(57) Abstract</p> <p>A device and method for processing a biological fluid comprises directing the biological fluid in a first container (19) tangentially to a first surface (16a) of a separation medium (16) in a first liquid flow path (14) of a housing (10) such that a plasma-rich fluid passes through a second surface (16b) of the separation medium (16) in a second liquid flow path (15) of the housing (10) and collected in a second container (18) and a plasma-depleted fluid passes tangentially to the first surface (16a) of the separation medium (16) and collected in a third container (17).</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

DEVICE AND METHOD FOR SEPARATING PLASMA FROM  
A BIOLOGICAL FLUID

Technical Field

The present invention concerns a device and  
5 method for separating plasma from a biological fluid  
such as blood.

Background of the Invention

An adult human contains about 5 liters of  
blood, of which red blood cells account for about  
10 45% of the volume, white cells about 1%, and the  
balance being liquid blood plasma. Blood also  
contains large numbers of platelets. In view of the  
substantial therapeutic and monetary value of blood  
components such as red blood cells, platelets, and  
15 plasma, a variety of techniques have been developed  
to separate blood into its component fractions while  
ensuring maximum purity and recovery of each of the  
components.

Typically, donated blood is collected in a  
20 blood collection bag and separated by centrifugation  
into PRC and platelet-rich plasma (PRP) fractions,  
the latter of which is in current practice separated  
by a second centrifugation to provide plasma and PC.  
With respect to the second centrifugation step, the  
25 platelet concentrate is typically obtained from the  
PRP by "hard-spin" centrifugation (rotating at about  
5000 G). This hard-spin compacts the platelets into  
a pellet or concentrate at the bottom of the test  
tube, flask, or bag. The plasma component is then  
30 removed or expressed to a separate bag or container,  
leaving the platelet component and some plasma  
behind. This platelet composition, which tends to  
form a dense aggregate, is subsequently dispersed to

make PC. The dispersion step is usually carried out by gentle mixing, for example, by placing the bag on a moving table which rotates with a precessing tilted motion.

5 Platelet concentrate can also be prepared using apheresis of autologous blood. With this method, whole blood is removed from a single donor, and centrifuged into its component parts. The desired component is then harvested and the remainder of the 10 blood is returned to the donor. This procedure allows collection of multiple units from one donor. Typically, a 2 to 3 hour apheresis procedure will 15 produce a platelet product containing  $3 \times 10^{11}$  platelets, equivalent to about six to ten units of random donor platelets, i.e., a typical transfusion unit. The common practice with respect to platelet concentrate is to transfuse a pool of six to ten units of platelets per administration, containing a total of about 300 to 700 ml of platelet 20 concentrate.

25 Blood bank personnel have responded to the increased need for blood components by attempting to increase packed red cell (PRC) and platelet concentrate (PC) yields in a variety of ways. For example, in separating the PRP from PRC, blood bank personnel have attempted to ensure that the entire PRP fraction is recovered, but this may be counter-productive, since the PRP, and the PC subsequently extracted from it, are frequently contaminated by 30 red cells, giving a pink or red color to the normally light yellow PC. The presence of red cells in PC is so highly undesirable that pink or red PC is frequently discarded, or subjected to re-centrifugation, both of which increase operating costs 35 and are labor intensive.

Additionally, freshly donated blood contains platelets varying in age from newly-formed to 9 days or more in age. Newly-formed platelets are larger, and are generally believed to be more active.

5 Because the younger platelets are larger, they tend to sediment faster during the first centrifugation step, and consequently are present in larger numbers in the PRP nearest to the red cell interface. Thus, although it is desirable to reclaim a larger 10 proportion of the younger, more active platelets, attempting to obtain a greater quantity poses a risk of contamination with red cells.

Typical techniques for processing platelets or platelet concentrate may reduce the yield and/or 15 adversely affect the platelets. For example, as noted earlier, during the separation of PRP from PRC, it is difficult to efficiently obtain the maximum yield of platelets while preventing red cells from entering the plasma. Additionally, hard 20 spin centrifugation and dispersion is labor intensive and it is believed that the forces applied during centrifugation may damage the platelets. For example, the hard-spin is potentially damaging to the platelets as it induces partial activation 25 agglomeration of the platelets and may cause physiological damage. Such agglomeration requires several hours to resuspend the platelets in solution before they can be used for transfusion into a patient. Additionally, the several hour dispersion 30 step is an undesirable delay, and is believed by many researchers to partially aggregate the platelet concentrate.

Furthermore, the hard-spin typically produces "distressed" platelets which partially disintegrate 35 upon resuspension. Unfortunately, while mixing does

prevent agglomeration, it encourages gas exchange by diffusion of oxygen through the walls of the bag (thereby controlling pH), and bathes the product in needed nutrients, this requires time, resulting in

5 an increase in the number and size of microaggregates. Further, over time, gel-like bodies may be formed, which may comprise fibrinogen, degenerated protein, and degenerated nucleic acids, which may interfere with the separation of the 10 platelets from the donated blood. Thus, some platelets are lost due to the process conditions.

Additionally, since platelets are notorious for being "sticky", an expression reflecting the tendency of platelets suspended in blood plasma to 15 adhere to any non-physiological surface to which they are exposed, the recovery of platelets may be adversely affected during the preparation of platelet concentrate, regardless of the method of preparation. Furthermore, under many circumstances, 20 platelets also adhere strongly to each other. Accordingly, in recovering platelets, it is desirable to restrict platelet loss to about 15% or less of the original platelet concentration.

Moreover, while leukocyte depletion of blood 25 components for transfusion may decrease risk to the patient, when leukocytes are removed from, for example, platelet-rich plasma, which typically results in the production of a leukocyte-free platelet concentrate, the platelet component of the 30 filtrate usually passes through a filter or separation device. In these systems, platelets may adhere to the surfaces of components of the separation device; such adhesion tends to cause substantial, and sometimes complete, removal of 35 platelets from the filtrate. Furthermore, platelet

concentrate present within the separation device at the completion of the separation process will be lost.

Disclosure of Invention

5 In describing the present invention, the following terms are used as defined below.

(A) Biological Fluid: Biological fluids include any treated or untreated fluid associated with living organisms, particularly blood, including 10 whole blood, warm or cold blood, and stored or fresh blood; treated blood, such as blood diluted with at least one physiological solution, including but not limited to saline, nutrient, and/or anticoagulant 15 solutions; blood components, such as platelet concentrate (PC), platelet-rich plasma (PRP), platelet-poor plasma (PPP), platelet-free plasma, plasma, packed red cells (PRC), or buffy coat (BC); analogous blood products derived from blood or a 20 blood component or derived from bone marrow; red cells separated from plasma and resuspended in physiological fluid; and platelets separated from plasma and resuspended in physiological fluid. The biological fluid may include leukocytes, or may be treated to remove leukocytes. As used herein, blood 25 product or biological fluid refers to the components described above, and to similar blood products or biological fluids obtained by other means and with similar properties.

A "unit" is the quantity of biological fluid 30 from a donor or derived from one unit of whole blood. It may also refer to the quantity drawn during a single donation. Typically, the volume of a unit varies, the amount differing from patient to patient and from donation to donation. Multiple

units of some blood components, particularly platelets and buffy coat, may be pooled or combined, typically by combining four or more units.

5       B) Plasma-Depleted Fluid: A plasma-depleted fluid refers to a biological fluid which has had some quantity of plasma-rich fluid (defined below) removed therefrom, e.g., the platelet-rich fluid or platelet component obtained when plasma is separated from PRP, or the fluid which remains after plasma is 10 removed from whole blood. The separation of the plasma-rich fluid from the biological fluid produces a plasma-depleted fluid having an increased concentration of platelets and/or red cells on a volume basis. Typically, the plasma-depleted fluid 15 is a platelet-containing fluid.

20       C) Plasma-Rich Fluid: A plasma-rich fluid refers to the plasma portion or plasma component removed from a biological fluid, e.g., the plasma-rich fluid when plasma is separated from PRP, or the plasma which is removed from whole blood. The plasma-rich fluid separated from a biological fluid has an increased concentration of plasma on a volume basis. Typically, the plasma-rich fluid is the plasma-containing fluid that passes through a 25 separation medium. Exemplary plasma-rich fluids include platelet-poor plasma or platelet-free plasma.

30       D) Separation medium: A separation medium refers to a porous medium through which one or more biological fluids pass and which separates one component of the biological fluid from another. As noted in more detail below, the porous medium for use with a biological fluid may be formed from any natural or synthetic fiber or from a porous or 35 permeable membrane (or from other materials of

similar surface area and pore size) compatible with a biological fluid, typically a biological fluid containing platelets, e.g., whole blood or PRP. The surface of the fibers or membrane may be unmodified or may be modified to achieve a desired property.

5        Although the separation medium may remain untreated, the fibers or membrane are preferably treated to make them even more effective for separating one component of a biological fluid, 10      e.g., plasma, from other components of a biological fluid, e.g., platelets or red cells. The separation medium is preferably treated in order to reduce or eliminate platelet adherence to the medium. Any treatment which reduces or eliminates platelet 15      adhesion is included within the scope of the present invention. Furthermore, the medium may be surface modified in order to achieve a desired critical wetting surface tension (CWST), e.g., as disclosed in U.S. Patent Nos. 4,880,548 and 5,100,564, and 20      International Publication No. WO 92/07656 in order to increase the critical wetting surface tension (CWST) of the medium and to be less adherent of platelets. Defined in terms of CWST, a preferred range of CWST for a separation medium as provided by 25      the present invention is above about 53 dynes/cm, typically above about 70 dynes/cm. The CWST of the separation medium may be dictated by its intended use. Further, the medium may be subjected to gas plasma treatment, an exemplary purpose for which is 30      to reduce platelet adhesion.

35      The porous medium may be pre-formed, single or multi-layered, and/or may be treated to modify the surface of the medium. If a fibrous medium is used, the fibers may be treated either before or after forming the fibrous lay-up. It is preferred to

modify the fiber surfaces before forming the fibrous lay-up because a more cohesive, stronger product is obtained after hot compression to form an integral element.

5 The separation medium may be configured in any suitable fashion, such as a flat sheet, a composite of two or more layers, a corrugated sheet, a web, hollow fibers, or a membrane.

10 F) Tangential flow filtration: As used herein, tangential flow filtration refers to passing or circulating a biological fluid in a generally parallel or tangential manner to the surface of the separation medium.

15 The present invention provides a method for processing a biological fluid comprising: directing a biological fluid tangentially to the surface of a separation medium whereby plasma-rich fluid passes through the separation medium and plasma-depleted fluid passes tangentially across the separation

20 medium.

25 The present invention provides a device for removing plasma from a biological fluid comprising: a housing having an inlet and first and second outlets and defining a first liquid flow path between the inlet and the first outlet and a second liquid flow path between the inlet and the second outlet; and a separation medium positioned inside the housing tangentially to the first flow path and across the second flow path, the separation medium

30 being suitable for passing plasma therethrough.

35 The present invention provides a device for processing a biological fluid comprising: a housing having a first portion and a second portion; an inlet and a first outlet in the first portion and a first fluid flow path therebetween; a second outlet

in the second portion and a second fluid flow path between the inlet and the second outlet; and a separation medium positioned inside the housing between the first portion and the second portion and 5 tangentially to the first flow path and across the second flow path, the separation medium being suitable for passing plasma therethrough but not platelet-rich fluid.

The present invention provides a device for 10 treating a biological fluid comprising: a separation medium having first and second external surfaces and being suitable for passing plasma therethrough; and a housing defining first and second flow paths, the separation medium being disposed within the housing 15 wherein the first flow path extends tangentially to the first external surface of the separation medium and the second flow path extends from the first external surface through the separation medium to the second external surface.

The present invention provides for a system for 20 processing a biological fluid comprising: a housing having an inlet and first and second outlets and defining a first liquid flow path between the inlet and the first outlet and a second liquid flow path 25 between the inlet and the second outlet; a separation medium positioned inside the housing tangentially to the first flow path and across the second flow path, the separation medium being suitable for passing a plasma-rich fluid 30 therethrough, and a container in fluid communication with the second outlet. The system may also include another container in fluid communication with the first outlet.

The invention involves the treatment of a 35 biological fluid to non-centrifugally separate at

least one component from the biological fluid, e.g.,  
treating PRP to obtain plasma and PC, or separating  
plasma from whole blood. Processes and devices  
provided by the invention utilize a separation  
5 medium that allows the passage of plasma, but  
prevents passage of platelets and/or red cells,  
through the medium, thereby eliminating the need for  
"hard-spin" centrifugation or multiple  
centrifugations as processing steps. Tangential  
10 flow of a biological fluid parallel to the upstream  
surface of the separating medium permits the passage  
of plasma through the medium, while reducing the  
tendency for cellular components or platelets to  
adhere to the surface of the medium, thus assisting  
15 in the prevention of passage of platelets through  
the separation medium. The hydrodynamics of flow  
parallel to a surface are indeed believed to be such  
that during flow parallel to the surface, platelets  
develop a spin which causes them to be recovered  
20 from the surface.

The device and method of the present invention  
thus protect platelets and red blood cells from  
physiological damage, and directly and effectively  
minimize or eliminate loss or damage caused by the  
25 currently used centrifugal separation processes, by  
reducing or eliminating the exposure to harmful  
centrifugation. Furthermore, the platelets and/or  
red blood cells are not required to pass through yet  
another filtration device in order to be separated  
30 from PRP. A feature of the separation device of the  
invention, therefore, is the increased yield of  
clinically and therapeutically superior platelet  
concentrate and/or platelet-free (or platelet-poor)  
plasma.

35 Advantageous features of the devices and

methods of the present invention include the separation of at least one component of a biological fluid from the rest of the fluid with minimal loss or activation of platelets. Platelet function is 5 believed to be only minimally affected by the separation process, and platelet survival time within the patient is believed to be significantly longer. Further, because of the high cost and increased demand for both platelet preparations and 10 plasma, as well as the clinical need to deliver a maximum therapeutic dose, a device as provided by this invention can deliver a higher proportion of the platelets or plasma originally present in the sample. The present invention also provides for 15 reclaiming a larger proportion of the younger, more active platelets in a sample.

This invention also provides for a device and method for separating platelet-poor plasma or platelet-free plasma from a biological fluid, such 20 as PRP or from whole blood, without requiring rotation, spinning, or centrifugation to effect the separation. For example, the instant invention provides for the separation of plasma from whole blood without centrifugation. Additionally, the 25 present invention provides for processing of PRP to form PC and plasma without hard-spin centrifugation.

The present invention further provides for maximum recovery of plasma from whole blood or from PRP.

30 Additionally, since some currently used procedures for processing biological fluid require several hours for completion, the present invention reduces processing time.

Brief Description of Drawings

Figure 1 is an elevation of an embodiment of the present invention.

5 Figure 2 is an elevation of another embodiment of the present invention.

Figure 3 is a cross-section of Figure 2, along E--E, showing the first fluid flow path in a separation device as provided by the invention.

10 Figure 4 is a section of Figure 3, along A--A.

Figure 5 is a section of Figure 3, along B--B.

Figure 6 is a cross-section of an embodiment of the invention showing the second fluid flow path in a separation device as provided by the invention.

Figure 7 is a section of Figure 6, along C--C.

15 Figure 8 is a section of Figure 6, along D--D.

Modes for Carrying Out the Invention

The present invention involves the separation of one or more components from a biological fluid.

20 As provided by the present invention, a biological fluid, particularly blood, is exposed to a separation medium suitable for passing plasma therethrough, but not platelets and/or red cells. Clogging of the separation medium by platelets and/or red cells is minimized or prevented.

25 The device of the present invention may be incorporated into a system which includes one or more containers in fluid communication with the inlet and/or outlets of the separation device.

Exemplary biological fluid processing systems, 30 which may be closed and/or sterile systems, are shown in Figures 1 and 2. Biological fluid processing system 100 may include a first container such as a collection bag or syringe 19; a separation device 200 including a separation medium 16; a

second container (first satellite bag) 18; a third container (second satellite bag) 17. The processing system 100 may also include at least one functional biomedical device, for example, a pump 90, and/or 5 other functional biomedical devices, including filtration and/or separation devices (not shown).

The components of the biological fluid processing system may be in fluid communication through conduits. For example, as illustrated in 10 Figure 1, conduits 50A, 50B, and 50C may be used to provide fluid communication between the components of the system. The biological fluid processing system may also include a seal, valve, clamp, transfer leg closure, stopcock, or the like located 15 within or on at least one of the conduits and/or the containers.

As illustrated in Figure 2, a separation device as provided by the invention generally comprises a housing 10 which includes an inlet 11 and first and 20 second outlets 12 and 13, respectively; a first fluid flow path 14 between the inlet 11 and the first outlet 12; and a second fluid flow path 15 between the inlet 11 and the second outlet 13. A separation medium 16 having first and second 25 surfaces 16a, 16b is positioned inside the housing 10, the separation medium being positioned parallel to the first fluid flow path 14 and across the second fluid flow path 15.

As depicted in Figure 2, in a separation device 30 200, the housing 10 includes first and second portions 10a and 10b, and the separation medium 16 is positioned inside the housing 10 between the first and second housing portions 10a, 10b. The first and second housing portions 10a, 10b may be 35 joined in any convenient manner, for example, by

ultrasonic or heat welding, an adhesive, a solvent, or one or more connectors.

Each of the components of the invention will now be described in more detail below.

5 Embodiments of the present invention may be configured in a variety of ways to ensure maximum contact of the biological fluid with the first surface 16a of separation medium 16 and to reduce or eliminate clogging on the first surface 16a of the separation medium. For example, the separation device includes one or more channels, grooves, conduits, passages, or the like which may be serpentine, parallel, curved, or a variety of other configurations facing the first surface 16a of the separation medium 16. Alternatively, the separation device may include a first shallow chamber facing the first surface 16a of the separation medium 16. The first chamber may include an arrangement of ribs which spread the flow of biological fluid over the 10 entire first surface 16a of the separation medium 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999

16. Extending along the first surface 16a, the serpentine fluid flow channels 20, 21, and 22 may be recombined at first outlet 12 of the housing 10.

Embodiments of the present invention may also 5 be configured in a variety of ways to minimize back pressure across the separation medium 16 and to ensure a sufficiently high velocity of flow to the second outlet 12 to prevent fouling of surface 16a, while minimizing hold-up volume. The separation 10 device may include an arrangement of ribs or may comprise one or more channels, grooves, conduits, passages, or the like which may be serpentine, parallel, curved, or have a variety of other configurations facing the second surface 16b of the 15 separation medium. Alternatively, the separation device may include a second shallow chamber facing the second surface 16b of the separation medium 16.

The fluid flow channels may be of any suitable 20 design and construction. For example, the channels may have a rectangular, semi-circular, or triangular cross section and a constant or variable depth and/or width. In the embodiment shown in Figures 6-8, several serpentine fluid flow channels 31, 32, 33, 34, and 35 face the second surface 16b of the 25 separation medium 16. Extending along the second surface 16b, the serpentine fluid flow channels 31-35 may be recombined at the second outlet 13.

Ribs, walls, or projections 41, 42, 43, 44, and 45 may be used to define the channels 20-22, 31-35 30 of the first and second chambers and/or may support or position the separation medium 16 within the housing 10. In a preferred embodiment of the invention, there are more walls in the second chamber than in the first chamber to prevent 35 deformation of the separation medium 16 caused by

pressure differential through the separation medium.

An exemplary channel depth may be in the range from about 0.635 cm (about 0.250 inch) to about 0.0025 cm (about 0.001 inch). An exemplary channel width may be in the range from about 0.635 cm (about 0.250 in) to about 0.025 cm (about 0.010 inch).

The housing and the separation medium of the present inventive device may be of any suitable configuration and material. For example, the housing, including the channels, ribs, walls, and/or projections may be formed from a material that is substantially impermeable to the biological fluid and substantially unreactive with the biological fluid. In the illustrated embodiment, the channels are defined by three sides which are substantially impermeable to and substantially unreactive with the biological fluid, and one side, i.e., defined by the separation medium, that is permeable to the biological fluid. Alternatively, the channels may be defined by two substantially impermeable and substantially unreactive sides and two permeable sides. For example, in one configuration, the opposing sides of a channel may each face a separation medium, allowing plasma-rich fluid to flow through each separation medium, and plasma-depleted fluid to flow tangentially to each separation medium. In another variation, e.g., involving a half-round configuration, at least one side of the channel is substantially impermeable to and substantially unreactive with the biological fluid.

While the preferred device has one inlet and two outlets, other configurations can be employed without adversely affecting the proper functioning of the device. For example, multiple inlets for a

biological fluid may be used so long as the biological fluid flows tangentially to the face of the separation medium. Alternatively, a single inlet and a single outlet may be used. For example, 5 a separation device may be configured to provide for two liquid flow paths such that both liquid flow paths communicate with the inlet, but only one liquid flow path communicates with both the inlet and the outlet.

10 The separation medium may be arranged in the separation device in any suitable manner so long as the biological fluid flow tangential or parallel to the separation medium is maintained to a sufficient extent to avoid or minimize substantial platelet 15 adhesion to the separation medium. One skilled in the art will recognize that platelet adhesion may be controlled or affected by manipulating any of a number of factors: velocity of the fluid flow, configuration of the channel, depth and/or width of 20 the channel, varying the depth and/or varying the width of the channel, the surface characteristics of the separation medium, the smoothness of the medium's surface, and/or the angle at which the fluid flow crosses the face of the separation 25 medium, among other factors. For example, the velocity of the first fluid flow is sufficient to remove platelets from the surface of the separation medium. Without intending to be limited thereby, a velocity in excess of about 30 cm/second has been 30 shown to be adequate.

35 The velocity of the fluid flow may also be affected by the volume of the biological fluid, by varying the channel depth, and by varying the channel width. For example, as shown in Figure 4, the channel depth may be varied from about 0.635 cm

(about 0.250 in) in the region 23 near the inlet 11 to about 0.0025 cm (about 0.001 in) in the region 24 near the outlet 12. One skilled in the art will recognize that a desired velocity may be achieved by 5 manipulating these and other elements. Also, platelets may not adhere as readily to a separation medium having a smooth surface as compared to a medium having a rougher surface.

A separation medium, as provided by the present 10 invention, comprises a porous medium suitable for passing plasma-rich fluid therethrough. The separation medium, as used herein, may include but is not limited to polymeric fibers (including hollow fibers), polymeric fiber matrices, polymeric 15 membranes, and solid porous media. Separation media in accordance with the invention separate plasma from a biological fluid containing platelets, typically whole blood or PRP, without allowing a substantial amount of platelets and/or red cells to 20 pass therethrough.

A separation medium according to the invention 25 preferably exhibits an average pore rating generally or intrinsically smaller than the average size of platelets. Preferably, platelets do not adhere to the surface of the separation medium, thus reducing pore blockage. The separation medium should also have a low affinity for proteinaceous components in the biological fluid such as PRP or whole blood. This enhances the likelihood that the plasma-rich 30 fluid, e.g., platelet-free plasma, will exhibit a normal concentration of proteinaceous clotting factors, growth factors, and other needed components. The separation medium and device also enhances the likelihood that complement activation 35 will be avoided.

In accordance with the invention, a separation medium formed of fibers may be continuous, staple, or melt-blown. The fibers may be made from any material compatible with a biological fluid

5 containing platelets, e.g., whole blood or PRP, and may be treated in a variety of ways to make the medium more effective. Also, the fibers may be bonded, fused, or otherwise fixed to one another, or they may simply be mechanically entwined. A

10 separation medium, as the term is used herein, may refer to one or more porous polymeric sheets, such as a woven or non-woven web of fibers, with or without a flexible porous substrate, or may refer to a membrane formed, for example, from a polymer

15 solution in a solvent by precipitation of a polymer when the polymer solution is contacted by a solvent in which the polymer is not soluble. The porous, polymeric sheet will typically be microporous, e.g., having a substantially uniform, continuous matrix

20 structure containing a myriad of small largely interconnected pores.

The separation medium of this invention may be formed, for example, from any synthetic polymer capable of forming fibers or a membrane. While not necessary to the apparatus or method of the invention, in one variation the polymer is capable of serving as a substrate for grafting with ethylenically unsaturated monomeric materials. In this variation, the polymer should be capable of reacting with at least one ethylenically unsaturated monomer under the influence of ionizing radiation or other activation means without the matrix being adversely affected. Suitable polymers for use as the substrate include, but are not limited to, polyolefins, polyesters, polyamides, polysulfones,

polyarylene oxides and sulfides, and polymers and copolymers made from halogenated olefins and unsaturated nitriles. Preferred polymers are polyolefins, polyesters, and polyamides, e.g.,

5 polybutylene terephthalate (PBT) and nylon. In an embodiment, a polymeric membrane may be formed from a fluorinated polymer such as polyvinylidene difluoride (PVDF). The most preferred separation media are a microporous polyamide membrane or a

10 polycarbonate membrane.

Exemplary separation media include but are not limited to those disclosed in International Publication No. WO 92/07656 and U.S. Patents

4,886,836; 4,906,374; 4,964,989; 4,968,533; and

15 5,019,260, which may include separation media having a water permeability of up to about 0.023 L/min/Pa/m<sup>2</sup> (about 15.0 L/min/psid/ft<sup>2</sup>).

Surface characteristics of a fiber or membrane can be modified by a number of methods, for example,

20 by chemical reaction including wet or dry oxidation, by coating the surface through deposition of a polymer thereon, by grafting reactions which are activated by exposure to an energy source such as heat, a Van der Graff generator, ultraviolet light, or to various other forms of radiation, and by treatment of the fibers or membrane with a gas plasma. A typical method for treatment with a gas plasma utilizes radio frequency (RF) discharge, with or without one or more polymerizable species. A

25 typical method for a grafting reaction uses gamma-radiation, for example, from a cobalt source.

30 Radiation grafting, when carried out under appropriate conditions, has the advantage of considerable flexibility in the choice of reactants, surfaces, and in the methods for activating the

required reaction. Gamma-radiation grafting is particularly preferable because the products are very stable and have undetectably low aqueous extractable levels. Furthermore, the ability to 5 prepare synthetic organic fibrous media having a CWST within a desired range is more readily accomplished using a gamma radiation grafting technique.

An exemplary radiation grafting technique 10 employs at least one of a variety of monomers each comprising an ethylene or acrylic moiety and a second group, which can be selected from hydrophilic groups (e.g., -COOH, or -OH) or hydrophobic groups (e.g., a methyl group or saturated chains such as 15 -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>). Grafting of the fiber or membrane surface may also be accomplished by compounds containing an ethylenically unsaturated group, such as an acrylic moiety, combined with a hydroxyl group, such as, hydroxyethyl methacrylate (HEMA). 20 Use of HEMA as the monomer contributes to a very high CWST. Analogues with similar characteristics may also be used to modify the surface characteristics of fibers.

In a variation of the invention, the separation 25 medium is surface modified by grafting thereon a hydroxyl-containing monomer to provide a separation medium having a low affinity for proteinaceous substances. For example, as described in U.S. Patent 4,906,374, the separation medium, which is 30 preferably a skinless membrane, may be surface modified using hydroxyl-containing unsaturated monomers, more typically monofunctional unsaturated monomers rich in pendant hydroxyl groups or groups capable of reacting to form hydroxyl groups, which 35 are capable of undergoing polymerization and

covalently bonding to the substrate under the influence of ionizing radiation. The most preferred hydroxyl-containing monomers are those in which the hydroxyl group is pendant, i.e., the group is not attached to a carbon atom which forms part of the polymer's backbone but is bound to a carbon atom that is separated from the backbone as, for example, a branching carbon atom. Suitable monomeric compounds should be substantially completely, if not totally, soluble in the solvents used. Solutions of the monomer compound may range in concentration of the monomer(s) from about 0.1 to about 5.0 percent, by weight, preferably about 0.2 to about 3.0 percent, by weight, based on the total weight of the solution.

In another variation of the invention, the separation medium is treated with a gas plasma, typically a low temperature gas plasma, with or without deposition of a polymeric substance formed by the plasma or introduced into the plasma. The term "plasma" or "gas plasma" is used generally to describe the state of an ionized gas. The use of the term "plasma" in this context should not be confused with "plasma" as it refers to a biological fluid. A gas plasma consists of high energy charged ions (positive or negative), electrons, and neutral species. As known in the art, a plasma may be generated by combustion, flames, physical shock, or, preferably, by electrical discharge, such as a corona or glow discharge.

In an exemplary gas plasma treatment technique, radio frequency (RF) discharge, a separation medium to be treated is placed in a vacuum chamber and the chamber is evacuated. Gas at low pressure is bled into the system through the gas inbleed until the

desired gas pressure differential across the conduit is achieved. An electromagnetic field is generated by subjecting the gas to a capacitive or inductive RF electrical discharge. The gas absorbs energy from the electromagnetic field and ionizes, producing high energy particles. The gas plasma, as used in the context of the present invention, is exposed to the separation medium, thereby modifying the properties of the medium to provide it with characteristics not possessed by the untreated medium, e.g., improving its biocompatibility, and ability to reduce platelet adhesion.

The gas used to treat the surface of the medium may include inorganic and organic gases used alone or in combination according to need. In addition, the gas may be a vaporized organic material, such as an ethylenic monomer to be plasma polymerized or deposited on the surface of the fiber. One example of a suitable gas is oxygen.

Typical parameters for treatment with a gas plasma may include power levels from about 10 to about 3000 watts. The RF frequency may include about 1 kHz to about 100 MHz. Exposure times may include about 5 seconds to about 12 hours. The gas pressures may include about 0.001 to 100 torr; and a gas flow rate of about 1-2000 standard cc/min.

In accordance with the invention, the separation medium may be surface modified, typically by radiation grafting or gas plasma treatment, in order to achieve the desired performance characteristics, whereby platelets are concentrated with a minimum of medium blocking. It may also be desirable to surface modify the separation medium such that the resulting plasma solution contains essentially all of its native proteinaceous

constituents. Exemplary membranes having a low affinity for proteinaceous substances are disclosed in U.S. Patents 4,886,836; 4,906,374; 4,964,989; 4,968,533; and 5,019,260.

5        Suitable membranes in accordance with an embodiment of the invention may be skinless microporous membranes and may be produced by, for example, a solution casting method.

10      For the separation of about one unit of whole blood, a typical separation device as provided by the invention includes an effective pore size smaller than platelets on the average, typically less than about 4 micrometers, preferably less than about 2 micrometers.

15      A typical separation device as provided by the invention includes a separation medium having an effective surface area in the range of about  $1.94 \text{ cm}^2$  to about  $194 \text{ cm}^2$  (about  $0.3 \text{ in}^2$  to about  $30 \text{ in}^2$ ). As used herein, the term effective surface area refers 20 to the surface area contacted by the biological fluid.

25      A preferable ratio of the wetted surface area of the fluid flow channel to the volume of the channel ( $A/V$ ) is in the range of about  $6.3 \text{ cm}^{-1}$  to about  $866 \text{ cm}^{-1}$  (about  $16 \text{ in}^{-1}$  to about  $2,200 \text{ in}^{-1}$ ).

30      The permeability of the separation medium is sufficient to allow the passage of a desirable amount of a fluid therethrough at a reasonable pressure in a reasonable amount of time. With respect to biological fluid, a preferred permeability is in the range of from about  $0.00078 \text{ L/min/Pa/m}^2$  to about  $0.023 \text{ L/min/Pa/m}^2$  (about  $0.5$  to about  $15.0 \text{ L/min/psid/ft}^2$ ). With respect to plasma, a preferred permeability is in the range of from 35 about  $0.00078 \text{ L/min/Pa/m}^2$  to about  $0.0078 \text{ L/min/Pa/m}^2$

(about 0.5 to about 5.0 L/min/psid/ft<sup>2</sup>), more preferably in the range of about 0.0011 L/min/Pa/m<sup>2</sup> to about 0.0047 L/min/Pa/m<sup>2</sup> (about 0.7 to about 3.0 L/min/psid/ft<sup>2</sup>).

5        The permeability and size of a typical separation device as provided by the present invention is preferably sufficient to produce about 160 cc to about 240 cc of plasma at reasonable pressures (e.g., less than about  $6.9 \times 10^5$  Pa (100 10      psi), more preferably, less than about  $1.38 \times 10^5$  (20 psi) in a reasonable amount of time (e.g., less than about one hour).

15      As provided by the present invention, all of these typical parameters may be varied to achieve a desired result, e.g., varied preferably to minimize platelet loss, to maximize plasma-rich fluid production, and/or to establish a certain flow rate.

20      The separation device may be positioned in the system of the instant invention in a variety of locations. For example, as illustrated in Figure 2, it may be located downstream of first container 19 and upstream of second container 18 and third container 17 respectively. Alternatively, as illustrated in Figure 1, it may be interposed 25      between first container 19 and second container 18.

30      A system as provided by the present invention may be used in conjunction with other functional biomedical devices, including filtration and/or separation devices, e.g., a device for removing leukocytes from a platelet-containing fluid or platelet concentrate. Exemplary functional biomedical devices are disclosed in U.S. Patent Nos. 4,880,548, 4,925,572, and 5,100,564; and International Publication Nos. WO 92/07656 and WO 35      91/17809. A functional biomedical device, as used

herein, refers to any of a number of devices, assemblies, or systems used in the collection and/or processing of biological fluids, such as whole blood or a blood component. Exemplary functional

5 biomedical devices include biological fluid containers, such as collection, transfer, and storage bags; conduits and connectors interposed between the containers; clamps, closures, and the like; air or gas inlet or outlet devices; a debubbler; a pump; and a red cell barrier device or 10 assembly. The functional biomedical device may also include a device for destroying biological contaminants, such as a high intensity light wave chamber, or a device for sampling a biological 15 fluid.

The present inventive device may similarly be part of an apheresis system. The biological fluid to be processed, the platelet-rich solution, and/or the platelet-poor solution may be handled in either 20 a batch or continuous manner. The sizes, nature, and configuration of the present inventive device can be adjusted to vary the capacity of the device to suit its intended environment.

The processing of biological fluid in the 25 context of the present invention may take place at any suitable time, which may be soon after donation. For example, when the biological fluid is donated whole blood, it is typically processed as soon as practicable in order to maximize the number of 30 components derived and to maximize blood component viability and physiological activity. Early processing may more effectively reduce or eliminate contaminating factors, including, but not limited to, leukocytes and microaggregates.

35 A method as provided by the invention may be

described in more detail with reference to Figures 1 and 2. Typically, a unit of a biological fluid, (e.g., donor's whole blood, or PRP) may be received into a first container 19 such as a collection bag or syringe for processing.

5 Movement of the biological fluid through the device and/or through the system may be effected by maintaining a pressure differential between a container such as a collection bag or a syringe 10 containing the biological fluid, and the destination of the biological fluid (e.g., a container such as a satellite bag), to cause the fluid to flow in a desired direction. Exemplary means for creating this pressure differential may be by gravity head, 15 applying pressure to the container (e.g., by hand or with a pressure cuff), by placing the satellite bag in a chamber which establishes a pressure differential between the satellite bag and the collection bag, e.g., a vacuum chamber or by a pump. 20 It is intended that the present invention is not to be limited by the means of creating the pressure differential.

With reference to Figures 1 and 2, the biological fluid is processed by directing it from 25 the container 19 to separation medium 16 so that the biological fluid flows tangentially to the surface of the separation medium. Directing the biological fluid to the separation medium may include channelling the biological fluid tangentially to the 30 surface of the separation medium such that a plasma-rich fluid passes tangentially across the separation medium and a plasma-rich fluid passes through the separation medium.

As noted above, establishing a tangential flow 35 of the biological fluid being processed parallel

with or tangential to the face of the separation medium minimizes platelet collection within or passage through the separation medium. As provided by the invention, the tangential flow can be induced by any mechanical configuration of the flow path which induces a high local fluid velocity at the immediate membrane surface. The tangential flow of the biological fluid may be directed tangential or parallel to the face of the separation medium in any suitable manner, preferably utilizing a substantial portion of the separation medium surface while maintaining a sufficient flow to ensure that the platelets do not clog or block the pores of the separation medium.

The flow of the biological fluid is preferably directed tangentially or parallel to the face of the separation medium through the use of at least one fluid flow channel which is designed to maximize utilization of the separation medium, ensure a sufficiently total area contact between the biological fluid and the separation medium, and maintain a sufficient flow of biological fluid to minimize or prevent platelet adhesion to the separation medium. Most preferably, several (e.g., three or more) uniform, serpentine, fluid flow channels are utilized so as to induce a high local fluid velocity along the entire immediate membrane surface and to fix the separation medium in place and to prevent sagging of the membrane due to the applied pressure. In the embodiments illustrated in Figures 3 and 6, three fluid flow channels are utilized in the first flow path, and five fluid flow channels are utilized in the second fluid flow path.

The fluid flow channels may be of any suitable design and construction and preferably are variable

with respect to depth to maintain optimal pressure and fluid flow across the face of the separation medium. By providing fluid flow channels, e.g., serpentine fluid flow channels, the biological fluid flows through each channel at a velocity high enough to sweep clean the surface of the separation medium and prevent platelets, red cells, or other material from fouling the medium. By providing several channels, the velocity of the fluid is uniformly high across the entire surface of the separation medium. Consequently, no eddys or stagnant areas of the biological fluid develop where platelets, red cells, or other material may settle upon, stick to, and foul the separation medium. Fluid flow channels may also be utilized on the side of the separation medium opposite the biological fluid tangential flow to control the flow rate and pressure drop of a platelet-poor fluid, such as plasma.

In an exemplary method, the biological fluid enters inlet 11 of housing 10 as shown in Figure 2. From the inlet 11, the fluid enters the channels 20-22 of the first chamber and passes tangentially or parallel to the first surface 16a of the separation medium 16 on the way to the first outlet 12 via the first fluid flow path 14. Plasma-rich fluid passes through the separation medium 16, and enters the channels 31-35 of the second chamber, and is directed toward the second outlet 13 via the second fluid flow path 15.

As the biological fluid continues along the first flow path 14 tangentially or parallel to the first surface 16a of the separation medium 16, more and more plasma-rich fluid crosses the separation medium 16. A plasma-depleted fluid, e.g., a platelet-containing fluid, then exits the housing 10

5 at the first outlet 12 while plasma-rich fluid exits the housing 10 at the second outlet 13. Typically, the plasma-rich fluid may be stored in a region separated from the separation medium in order to avoid possible reverse flow of the plasma-rich fluid back across the separation medium to the plasma-depleted fluid.

10 The plasma-rich fluid exiting at the second outlet 13, and/or the plasma-depleted fluid exiting at the first outlet 12, may be further processed. For example, as shown in Figure 2, additional processing may include collecting the fluids in separate containers, such as first satellite bag 18 and second satellite bag 17. As shown in Figure 1, 15 additional processing may include re-directing the plasma-depleted fluid to the separation medium to deplete additional amounts of plasma. The plasma-depleted fluid may be repeatedly recirculated through the separation device, e.g., until the 20 plasma-depleted fluid contains a pre-determined amount or concentration of platelets.

25 The biological fluid may be supplied in any suitable quantity consistent with the capacity of the overall device and by any suitable means, e.g., in a batch operation by, for example, a blood bag connected to an expressor or a syringe, or in a continuous operation as part of, for example, an apheresis system.

30 In order that the invention herein described may be more fully understood, the following examples are set out regarding use of the present invention. These examples are for illustrative purposes only and are not to be construed as limiting the present invention in any manner.

35 EXAMPLE 1.

Whole blood was collected into an Adsol™ donor set and was processed under standard conditions to yield a unit of PRP. The PRP was then filtered to remove leukocytes using a filter device described in 5 U.S. Patent 4,880,548. The removal efficiency was >99.9%.

The filtered PRP unit was then placed in a pressure cuff to which a pressure of 300 mm Hg was applied. The tubing exiting the bag (clamped closed 10 at this point) was connected to the inlet port of a separation device as shown in Figures 3-6. A microporous polyamide membrane having a pore rating of 0.65 microns was used as the separation medium in the device. The area of the membrane was about 17.4 15 square centimeters. The depth of the first fluid flow path channels decreased from about 0.03 cm near the inlet to about 0.01 cm near the outlet. The depth of the second fluid flow path channels was about 0.025 cm. The width of the channels was 0.084 20 cm. The outlet ports of the device were connected to tubing which allowed the volume of fluid exiting the device to be measured and saved for analysis.

The test of the present invention was started by opening the clamp and allowing PRP to enter the 25 device. Clear fluid (plasma) was observed to exit one port, and turbid fluid (platelet concentrate) exited the other port. The duration of the test was 42 minutes, during which 154 ml of plasma and 32 ml of platelet concentrate was collected. The 30 concentration of platelets in the plasma was found to be  $1.2 \times 10^4/\mu\text{l}$ , while the concentration of platelets in the platelet concentration was found to be  $1.43 \times 10^6/\mu\text{l}$ .

The above results indicate that PRP can be 35 concentrated to a useful level, and platelet-poor

plasma recovered, in a reasonable time by a device provided by the invention.

EXAMPLE 2.

5 A sample of 450 ml of whole blood was collected under standard conditions from a human donor and placed in a typical flexible plastic blood bag. An analysis of the whole blood sample indicates that it contained about 203 ml plasma. A 2 cc whole blood sample was withdrawn from the bag in a 5 cc syringe 10 and attached to the inlet port of a device as provided by the invention as shown in Figure 2.

15 The present inventive device included a serpentine fluid flow path with a channel length of 32.5 cm, a constant width of 0.081 cm, and a constant depth of 0.013 cm. The fluid flow path was of a "C" cross-section and, on its open side, 20 contacted a microporous polycarbonate membrane having a pore rating of 0.4 microns which served as the separation medium. About  $26.4 \text{ cm}^2$  of the microporous membrane were thereby part of the fluid 25 flow path and were capable of being contacted by the whole blood sample or processed fluid as it passed through the device in the fluid flow path. Fluid flowed through the separation medium at a rate of 0.2 ml/min. The entire whole blood sample was processed in about 2 minutes. Air in the syringe 30 was used to drive any hold-up through the device.

At the conclusion of the processing, a total of about 1.6 cc of turbid fluid (red cell containing fraction) and .4 cc of clear fluid was collected 35 from the processing of the whole blood sample. An analysis of the clear fluid indicated that it was plasma.

The above results indicate that plasma can be removed from whole blood in a reasonable time

through the use of the present invention.

EXAMPLE 3.

A sample of 450 ml of whole blood is collected under standard conditions from a human donor and 5 placed in a typical flexible plastic blood bag. An analysis of the whole blood sample indicates that the hematocrit is 37%, indicating that the sample includes about 283.5 cc plasma and 166.5 cc red cells. A 2 cc whole blood sample is withdrawn from 10 the bag in a 5 cc syringe and attached to the inlet port of a device comprising a serpentine fluid flow path similar to that described in Example 2.

At the conclusion of the processing a total of about .75 cc of turbid fluid (red cell containing 15 fraction) and 1.25 cc of clear fluid is collected from the processing of the whole blood sample. An analysis of the clear fluid indicates that it is plasma.

The above results indicate that plasma can be 20 efficiently removed from whole blood in a reasonable time through the use of the present invention.

EXAMPLE 4.

A source bag and a satellite bag were connected to a separation device and a peristaltic pump in a 25 configuration similar to that of Figure 1. The source bag contained a unit of leukocyte depleted PRP (approximately 200 ml). Tubing connected the source bag to the inlet port of the separation device, and, to provide for recirculation, tubing 30 connected the first outlet port of the separation device to the source bag. Additionally, tubing connected the second outlet port of the separation device to the satellite bag.

A peristaltic pump was associated with the 35 tubing between the source bag and the inlet port of

the separation device to provide for fluid flow.

The satellite bag was placed on a scale so that

the amount of plasma entering the bag could be

monitored. The peristaltic pump was activated at a

5 flow rate of 25 cc/min and PRP was drawn from the

source bag into the device. Clear fluid (plasma)

exited the second port and entered the satellite

bag. Turbid fluid (containing platelets) exited the

first port and was recirculated into the source bag.

10 The source bag was periodically squeezed to increase

the mixing of the platelets in the fluid.

After approximately 35 minutes, about 150 ml of

plasma was collected in the satellite bag and about

50 ml of platelet concentrate was collected in the

15 source bag.

The above results indicate that platelet

concentrate and platelet-poor plasma can be

recovered in a reasonable time, using recirculation

of fluid by a device provided by the invention.

20 While the invention has been described in some

detail by way of illustration and example, it should

be understood that the invention is susceptible to

various modifications and alternative forms, and is

not restricted to the specific embodiments set

25 forth. It should be understood that these specific

embodiments are not intended to limit the invention

but, on the contrary, the intention is to cover all

modifications, equivalents, and alternatives falling

within the spirit and scope of the invention.

Claims:

1. A method for processing a biological fluid comprising:

5 directing a biological fluid tangentially to the surface of a separation medium whereby plasma-rich fluid passes through the separation medium and plasma-depleted fluid passes tangentially across the separation medium.

10 2. The method of claim 1 further comprising recirculating plasma-depleted fluid to the separation medium.

15 3. The method of claim 1 wherein directing the biological fluid tangentially to the surface of the separation medium comprises passing the biological fluid through at least one flow channel.

4. The method of claim 1 further comprising passing the plasma-rich fluid through at least one flow channel.

20 5. The method of claim 1 further comprising directing the biological fluid tangentially to the surface of the separation medium at a sufficiently high velocity to sweep platelets from the surface of the medium.

25 6. The method of claim 1 comprising passing the biological fluid through two or more flow channels.

7. The method of claim 3 comprising passing the biological fluid through two or more serpentine flow channels.

8. A device for removing plasma from a biological fluid comprising:

a housing having an inlet and first and second outlets and defining a first liquid flow path between the inlet and the first outlet and a second liquid flow path between the inlet and the second outlet; and

5 between the inlet and the first outlet and a second liquid flow path between the inlet and the second outlet; and  
10 a separation medium positioned inside the housing tangentially to the first flow path and across the second flow path, the separation medium being suitable for passing plasma therethrough.

9. The device of claim 8 wherein said first fluid flow path comprises at least one fluid flow channel.

15 10. The device of claim 9 wherein said fluid flow channel is a serpentine fluid flow channel.

11. The device of claim 10 wherein said first fluid flow path comprises two or more fluid flow channels.

20 12. The device of claim 8 wherein said second fluid flow path comprises at least one fluid flow channel.

13. The device of claim 9 wherein said fluid flow channel or channels are configured to maintain 25 substantially constant velocity of the biological fluid passing therethrough.

14. The device of claim 9 wherein said fluid flow channel is deeper near the inlet than near the first outlet.

15. The device of claim 9 wherein said fluid flow channel decreases in depth over the length of the channel in the fluid flow direction.

16. The device of claim 12 wherein said fluid flow channel is a serpentine fluid flow channel.

5  
17. The device of claim 16 wherein said second fluid flow path comprises two or more fluid flow channels.

10  
18. A device for treating a biological fluid comprising:

a separation medium having first and second external surfaces and being suitable for passing plasma therethrough; and

15  
19. The separation medium being disposed within the housing wherein the first flow path extends tangentially to the first external surface of the separation medium and the second flow path extends from the first external surface through the separation medium to the second external surface.

20  
19. A system for processing a biological fluid comprising:

25  
a housing having an inlet and first and second outlets and defining a first liquid flow path between the inlet and the first outlet and a second liquid flow path between the inlet and the second outlet;

30  
a separation medium positioned inside the housing tangentially to the first flow path and across the second flow path, the separation medium being suitable for passing plasma therethrough but

not a platelet-rich fluid;  
a container in fluid communication with the  
first outlet.

20. A method for decreasing the plasma content  
5 of a biological fluid comprising:  
directing a biological fluid through the device  
of claim 8 tangentially to the surface of the  
separation medium whereby a platelet-poor fluid  
passes through the separation medium and a platelet-  
rich fluid is recovered.  
10

21. The method of claim 20 further comprising  
directing the biological fluid tangentially to the  
surface of the separation medium at substantially  
constant velocity.

15 22. The method of claim 21 comprising passing  
said biological fluid through at least one fluid  
flow channel tangentially to the surface of the  
separation medium.

23. The method of claim 22 comprising passing  
20 said biological fluid through a serpentine fluid  
flow channel.

24. The method of claim 20 further comprising  
recirculating platelet-rich fluid through the  
device.

25. 25. The system of claim 19 further comprising a  
closed system.

26. A device for processing a biological fluid  
comprising:

a housing having an inlet and at least one outlet and having a first liquid flow path and a second liquid flow path, wherein the second liquid flow path is located between the inlet and the

5 outlet; and

a separation medium positioned inside the housing tangentially to the first flow path and across the second flow path, the separation medium being suitable for passing plasma-rich fluid

10 therethrough.




FIG. 1




FIG. 2





FIG. 3






FIG. 6

FIG. 8





FIG. 7

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) :B01D 61/00

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 210/645, 654, 767, 321.6, 321.75, 483.496, 500.27; 422/48; 530/830

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 4,680,025 (Kruger et al) 14 July 1987, See entire document.	1-5,8-9,13, 18-22,24-26
X	US, A, 4,604,208 (Chu et al) 05 August 1986, See entire document.	1-5,8-9,13, 18-22,24-26
X	US, A, 4,806,247 (Schoendorfer et al) 21 February 1989, See entire document.	1-5,8-9,13, 18-22,24-26
X	US, A, 5,008,012 (Hagihara et al) 16 April 1991, See entire document.	1-5,8-9,13, 18-22,24-26
X	US, A, 4,746,436 (Kopp et al) 24 May 1988, See entire document.	1-5,8-9,13, 18-22,24-26

 Further documents are listed in the continuation of Box C.

See patent family annex.

• Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be part of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 DECEMBER 1992

Date of mailing of the international search report

15 JAN 1993

Name and mailing address of the ISA/  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer *Jyoti Malvi*  
*Jyoti Malvi*  
SUN UK KIM  
Telephone No. (703) 308-2350

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,049,268 (Kopf) 17 September 1991, See entire document.	6-7,10-12, 16-17,23

**A. CLASSIFICATION OF SUBJECT MATTER:**

US CL :

210/650, 651, 805, 321.84, 433.1; 422/101, 102; 604/6; 436/177, 178; 530/412, 414